<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00573508</url>
  </required_header>
  <id_info>
    <org_study_id>905-UC-010</org_study_id>
    <nct_id>NCT00573508</nct_id>
  </id_info>
  <brief_title>Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life</brief_title>
  <acronym>VIBRANT</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 4, Multi-center Study of VESIcare® (Solifenacin Succinate) in Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life VIBRANT: VESIcare® Investigation of BotheR And Quality of Life iN subjecTs With OAB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effect of VESIcare® on symptom bother for subjects with OAB
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 4, multi-center, randomized, double-blind, placebo-controlled, parallel group study.
      All subjects that meet the baseline criteria will be randomized in a 1:1 ratio into VESIcare®
      (solifenacin succinate) or placebo group.

      The study duration consists of a screening period which includes a minimum of a 14 day
      treatment free wash-out period. Subjects meeting the baseline criteria will have a 12 week
      treatment period. Maximum total study duration is 15 weeks: 2 3 week screening / washout
      period; 12 week double-blind treatment.

      Primary efficacy will be based on OAB-q symptom bother score.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to End of Treatment in Overactive Bladder Questionnairre (OAB-q) Symptom Bother Score</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>The OAB-q is used to assess how much a patient is bothered by OAB symptoms &amp; the impact of these symptoms on the patient's Health Related Quality of Life(HRQL). It is a patient administered tool comprised of 33 items, where the first 8 define symptom bother with raw score being converted to a scale of 0 to 100.
Higher score values are indicative of greater symptom severity or bother, and a lower score in change from baseline indicates improvement.
End of Treatment results include patients who had early discontinuation from the study.
Change is calculated as End of Treatment - Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Visit in Symptom Bother Utilizing the OAB-q Score</measure>
    <time_frame>Baseline, Week 4, Week 8 and Week 12</time_frame>
    <description>The OAB-q is used to assess how much a patient is bothered by OAB symptoms and the impact of these symptoms on the patient's HRQL. It is a validated patient administered tool comprised of 33 items, where the first 8 items define symptom bother with raw score being converted to a scale of 0 to 100.
Higher score values are indicative of greater symptom severity or bother, and a lower score in change from baseline indicates improvement.
Change is calculated as Actual Data for each timepoint - Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Visit in OAB-q Health Related Quality of Life (HRQL) Total Score</measure>
    <time_frame>Baseline, Week 4, Week 8 and Week 12</time_frame>
    <description>The OAB-q is used to assess how much a patient is bothered by OAB symptoms and the impact of these symptoms on the patient's HRQL. It is a validated patient administered tool comprised of 33 items, where items 9 - 33 define HRQL with raw score being converted to a scale of 0 to 100.
Higher score values are indicative of better HRQL, and a positive score in change from baseline indicates improvement.
Change is calculated as Actual Data for each time point - Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in the Global Assessment Score of the Patient Perception of Bladder Condition (PPBC)</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>The PPBC is a validated, global assessment tool using a 6-point Likert scale which requires patients to assess their bladder condition by selecting one of the following responses: 1=Does not cause me any problem at all; 2=Cause me some very minor problems; 3=Causes me some minor problems; 4=Causes me (some) moderate problems; 5=Causes me severe problems; 6=Causes me many severe problems
Improvement is defined by any reduction in PPBC score.
End of Treatment results include patients who had early discontinuation from the study.
Change is calculated as End of Treatment (EOT) - Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Treatment Benefit at the End of Treatment in the Global Assessment Score of the Benefit, Satisfaction, and Willingness (BSW) Questionnaire</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>The BSW questionnaire is a validated instrument that can be used to assess patient satisfaction with antimuscarinic agents for OAB. It is designed to capture the patient's perception of the effect of treatment in terms of relative benefit, patient satisfaction, and patient intention or willingness to continue on therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Visit in the OAB-q HRQL Sub-domain Scores of Coping, Concern, Sleep and Social</measure>
    <time_frame>Baseline, Week 4, Week 8 and Week 12</time_frame>
    <description>The OAB-q is used to assess how much a patient is bothered by OAB symptoms &amp; the impact on the patient's HRQL. It is comprised of 33 items, with raw scores for each sub-domain being converted to a scale of 0 to 100.
Higher score values are indicative of better HRQL, and a positive score in change from baseline indicates improvement.
Change is calculated End of Treatment (EOT) for each sub-domain - Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Work Productivity Assessment Index (WPAI)</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>The WPAI is a tool used to evaluate the effect of solifenacin succinate on a patient's overall satisfaction &amp; quality of life, and included 6 questions regarding the effect that bladder condition had on ability to perform work-related functions &amp; carry out daily activities over the past 4 weeks. The scores were converted to percentages for reporting.
A negative score in Change from Baseline indicates improvement. End of Treatment results include patients who had early discontinuation from the study.
Change from baseline is based on the ANCOVA model after adjusting baseline value &amp; center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Medical Care Use Index (MCUI) Medical Resource Utilization in the Past 3 Months</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>MCUI is a Patient Reported Outcome instrument utilized to further evaluate the effect of solifenacin succinate on patient's overall satisfaction and quality of life.The tool included questions concerning the effect of the patients bladder condition on access to medical care.
A negative score in Change from Baseline indicates improvement.
End of Treatment results include patients who had early discontinuation from the study.
Change is calculated as End of Treatment (EOT) - Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the MCUI Behavior Therapy Stratified</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>MCUI is a Patient Reported Outcome instrument utilized to further evaluate the effect of solifenacin succinate on patient's overall satisfaction and quality of life. The tool included questions concerning the effect of the patients bladder condition on access to medical care.
A negative score in Change from Baseline indicates improvement.
End of Treatment results include patients who had early discontinuation from the study.
Change is calculated as End of Treatment (EOT) - Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in International Consultation on Incontinence Modular Questionnaire Male Sexual Matters Associated With Lower Urinary Tract Symptoms (ICIQ-MLUTSsex) Overall Symptom and Bother Scores.</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>ICIQ-MLUTSsex is a patient reported outcome instrument to further evaluate the effect of solifenacin succinate on patients' overall satisfaction &amp; quality of life. The questionnaire contains 5 questions for detailed evaluation of sexual matters associated with lower urinary track symptoms &amp; impact on sexual quality of life, with a scale of 0 to 12.
Change from baseline with a negative score indicates improvement. End of Treatment results include patients who had early discontinuation. Change is calculated as End of Treatment(EOT)-Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in International Consultation on Incontinence Modular Questionnaire Female Sexual Matters Associated With Lower Urinary Tract Symptoms (ICIQ-FLUTSsex)Overall Symptom and Bother Scores.</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>ICIQ-FLUTSsex is a patient reported outcome instrument to further evaluate the effect of solifenacin succinate on patients' overall satisfaction &amp; quality of life.The questionnaire contains 5 questions for detailed evaluation of sexual matters associated with lower urinary track symptoms &amp; impact on sexual quality of life, with a scale of 0 to 14.
Change from baseline with a negative score indicates improvement. End of Treatment results include patients who had early discontinuation. Change is calculated as End of Treatment(EOT)-Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Treatment Satisfaction Visual Analog Scale (TS-VAS)</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>The TS-VAS is a instrument utilized to further evaluate the effect of solifenacin succinate on patients' overall satisfaction &amp; quality of life. Each patient completed a TS-VAS to rate satisfaction with treatment. They were to answer the following question: &quot;Are you satisfied with your treatment?&quot; by placing a mark on a line that ran from 0 (no, not at all) to 100 (yes, completely).
Change from baseline with a positive score indicates an improvement. The End of Treatment (EOT) results include patients who had early discontinuation from the study.
Change is calculated as EOT - Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Treatment in Mean Parameters Per 24 Hours Recorded in 3-day Diary</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>The mean parameters recorded for previous 24 hours in the 3-day diary were: number of micturitions, number of incontinence episodes, number of urgency episodes, number of nocturia episodes and number of nocturnal voids.
Change from baseline with a lower score indicates an improvement.
End of Treatment (EOT) results include patients who had early discontinuation from the study; only patients who had the symptom at baseline and data at the EOT in the 3-day diary are included in the data table.
Change is calculated as EOT - Baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">768</enrollment>
  <condition>Urinary Bladder, Overactive</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Matching placebo tablet taken once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin Succinate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg or 10mg tablet taken once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin Succinate</intervention_name>
    <description>Oral Administration</description>
    <arm_group_label>Solifenacin Succinate</arm_group_label>
    <other_name>VESIcare®</other_name>
    <other_name>YM905</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory male or female subject ≥ 18 years of age and able to use the toilet without
             difficulty

          -  History of OAB symptoms for ≥ 3 months

          -  An average of ≥ 8 micturitions per 24 hours and ≥ 1 urgency episode (with or without
             incontinence) per 24 hours as documented in a 3-day micturition diary

          -  Subjects are bothered by symptoms as reflected by PPBC ≥3

        Exclusion Criteria:

          -  Evidence of chronic urologic inflammation such as interstitial cystitis and bladder
             stones; uncontrolled narrow angle glaucoma; urinary or gastric retention

          -  Recurrent urinary tract infection (UTI) of &gt; 3 episodes within the last 3 months or
             evidence of a urinary tract infection at Baseline Visit (Visit 2)

          -  Significant stress incontinence or mixed stress/urge incontinence where stress is the
             predominant factor as determined by the investigator

          -  History of renal or hepatic impairment(2 x Upper Limit of Normal(ULN) values in
             parameters and considered clinically significant by the investigator

          -  History of diagnosed gastrointestinal obstruction disease

          -  Subject has a known diagnosis or history of carcinoma (including prostate cancer)
             except non metastatic basal or squamous cell carcinoma of the skin that has been
             successfully treated or previous pelvis radiation within the past five years

          -  Known or suspected hypersensitivity to solifenacin succinate, any components, or other
             anticholinergics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma US, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>67080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melrose Park</city>
        <state>Illinois</state>
        <zip>60160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <zip>14127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Central Point</city>
        <state>Oregon</state>
        <zip>97502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Lake</city>
        <state>Washington</state>
        <zip>98043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.astellas.us/docs/vesicare.pdf</url>
    <description>Link to Prescribing Information</description>
  </link>
  <results_reference>
    <citation>Vardy MD, Mitcheson HD, Samuels TA, Wegenke JD, Forero-Schwanhaeuser S, Marshall TS, He W. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. Int J Clin Pract. 2009 Dec;63(12):1702-14. doi: 10.1111/j.1742-1241.2009.02209.x.</citation>
    <PMID>19930331</PMID>
  </results_reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2007</study_first_posted>
  <results_first_submitted>February 2, 2010</results_first_submitted>
  <results_first_submitted_qc>September 7, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2010</results_first_posted>
  <last_update_submitted>September 7, 2010</last_update_submitted>
  <last_update_submitted_qc>September 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sr. Manager Clinical Trials Registry</name_title>
    <organization>Astellas Pharma US, Inc</organization>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching placebo tablet taken once daily</description>
        </group>
        <group group_id="P2">
          <title>Solifenacin Succinate</title>
          <description>5mg or 10mg tablet taken once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="382"/>
                <participants group_id="P2" count="386"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="374">Patients who took &gt;= 1 dose of double-blind study drug, had a baseline OAB-q &amp; &gt;= 1 subsequent visit</participants>
                <participants group_id="P2" count="377">Patients who took &gt;= 1 dose of double-blind study drug, had a baseline OAB-q &amp; &gt;= 1 subsequent visit</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="318"/>
                <participants group_id="P2" count="345"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching placebo tablet taken once daily</description>
        </group>
        <group group_id="B2">
          <title>Solifenacin Succinate</title>
          <description>5mg or 10mg tablet taken once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="382"/>
            <count group_id="B2" value="386"/>
            <count group_id="B3" value="768"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.4" spread="12.36"/>
                    <measurement group_id="B2" value="59.4" spread="13.44"/>
                    <measurement group_id="B3" value="59.4" spread="12.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="321"/>
                    <measurement group_id="B2" value="311"/>
                    <measurement group_id="B3" value="632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="333"/>
                    <measurement group_id="B2" value="347"/>
                    <measurement group_id="B3" value="680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian-Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Treatment in Overactive Bladder Questionnairre (OAB-q) Symptom Bother Score</title>
        <description>The OAB-q is used to assess how much a patient is bothered by OAB symptoms &amp; the impact of these symptoms on the patient's Health Related Quality of Life(HRQL). It is a patient administered tool comprised of 33 items, where the first 8 define symptom bother with raw score being converted to a scale of 0 to 100.
Higher score values are indicative of greater symptom severity or bother, and a lower score in change from baseline indicates improvement.
End of Treatment results include patients who had early discontinuation from the study.
Change is calculated as End of Treatment - Baseline.</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Population is full analysis set(FAS): all randomized patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.
The number of participants per arm is consistent for all categories / rows of the data table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Succinate</title>
            <description>5mg or 10mg tablet taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment in Overactive Bladder Questionnairre (OAB-q) Symptom Bother Score</title>
          <description>The OAB-q is used to assess how much a patient is bothered by OAB symptoms &amp; the impact of these symptoms on the patient's Health Related Quality of Life(HRQL). It is a patient administered tool comprised of 33 items, where the first 8 define symptom bother with raw score being converted to a scale of 0 to 100.
Higher score values are indicative of greater symptom severity or bother, and a lower score in change from baseline indicates improvement.
End of Treatment results include patients who had early discontinuation from the study.
Change is calculated as End of Treatment - Baseline.</description>
          <population>Population is full analysis set(FAS): all randomized patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.
The number of participants per arm is consistent for all categories / rows of the data table.</population>
          <units>OAB-q Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" spread="18.18"/>
                    <measurement group_id="O2" value="58.2" spread="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" spread="22.54"/>
                    <measurement group_id="O2" value="28.3" spread="20.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at End of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.4" spread="21.72"/>
                    <measurement group_id="O2" value="-29.9" spread="22.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical Analysis applies to 'Change at End of Treatment'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>9.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.6</ci_lower_limit>
            <ci_upper_limit>12.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Visit in Symptom Bother Utilizing the OAB-q Score</title>
        <description>The OAB-q is used to assess how much a patient is bothered by OAB symptoms and the impact of these symptoms on the patient's HRQL. It is a validated patient administered tool comprised of 33 items, where the first 8 items define symptom bother with raw score being converted to a scale of 0 to 100.
Higher score values are indicative of greater symptom severity or bother, and a lower score in change from baseline indicates improvement.
Change is calculated as Actual Data for each timepoint - Baseline.</description>
        <time_frame>Baseline, Week 4, Week 8 and Week 12</time_frame>
        <population>Population is full analysis set(FAS): all randomized patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Succinate</title>
            <description>5mg or 10mg tablet taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each Visit in Symptom Bother Utilizing the OAB-q Score</title>
          <description>The OAB-q is used to assess how much a patient is bothered by OAB symptoms and the impact of these symptoms on the patient's HRQL. It is a validated patient administered tool comprised of 33 items, where the first 8 items define symptom bother with raw score being converted to a scale of 0 to 100.
Higher score values are indicative of greater symptom severity or bother, and a lower score in change from baseline indicates improvement.
Change is calculated as Actual Data for each timepoint - Baseline.</description>
          <population>Population is full analysis set(FAS): all randomized patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
          <units>OAB-q Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline ( N= 374 ; 377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" spread="18.18"/>
                    <measurement group_id="O2" value="58.2" spread="18.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=371; 370)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6" spread="21.04"/>
                    <measurement group_id="O2" value="35.5" spread="20.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (N=371; 370)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4" spread="19.33"/>
                    <measurement group_id="O2" value="-22.6" spread="20.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (N=342; 356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" spread="21.86"/>
                    <measurement group_id="O2" value="29.8" spread="20.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8 (N=342; 356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.0" spread="20.64"/>
                    <measurement group_id="O2" value="-28.9" spread="22.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (N=318; 339)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" spread="21.91"/>
                    <measurement group_id="O2" value="27.6" spread="20.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (N=318; 339)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.7" spread="21.52"/>
                    <measurement group_id="O2" value="-30.9" spread="22.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical Analysis applies to 'Change at Week 4', 'Change at Week 8' and 'Change at Week 12'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Visit in OAB-q Health Related Quality of Life (HRQL) Total Score</title>
        <description>The OAB-q is used to assess how much a patient is bothered by OAB symptoms and the impact of these symptoms on the patient's HRQL. It is a validated patient administered tool comprised of 33 items, where items 9 - 33 define HRQL with raw score being converted to a scale of 0 to 100.
Higher score values are indicative of better HRQL, and a positive score in change from baseline indicates improvement.
Change is calculated as Actual Data for each time point - Baseline.</description>
        <time_frame>Baseline, Week 4, Week 8 and Week 12</time_frame>
        <population>Population is full analysis set(FAS): all randomized patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Succinate</title>
            <description>5mg or 10mg tablet taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each Visit in OAB-q Health Related Quality of Life (HRQL) Total Score</title>
          <description>The OAB-q is used to assess how much a patient is bothered by OAB symptoms and the impact of these symptoms on the patient's HRQL. It is a validated patient administered tool comprised of 33 items, where items 9 - 33 define HRQL with raw score being converted to a scale of 0 to 100.
Higher score values are indicative of better HRQL, and a positive score in change from baseline indicates improvement.
Change is calculated as Actual Data for each time point - Baseline.</description>
          <population>Population is full analysis set(FAS): all randomized patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
          <units>OAB-q HRQL Total Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N= 374 ; 377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.8" spread="21.34"/>
                    <measurement group_id="O2" value="56.4" spread="22.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=371; 370)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" spread="21.42"/>
                    <measurement group_id="O2" value="76.0" spread="20.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4(N=371; 370)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="17.92"/>
                    <measurement group_id="O2" value="19.3" spread="19.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (N=342; 356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" spread="21.06"/>
                    <measurement group_id="O2" value="80.5" spread="19.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8 (N=342; 356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="19.00"/>
                    <measurement group_id="O2" value="24.4" spread="21.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (N=318; 339)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" spread="20.53"/>
                    <measurement group_id="O2" value="82.2" spread="19.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12(N=318; 339)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="19.39"/>
                    <measurement group_id="O2" value="25.8" spread="22.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical Analysis applies to 'Change at Week 12'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>P-Value represents change from Baseline to Week 12.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in the Global Assessment Score of the Patient Perception of Bladder Condition (PPBC)</title>
        <description>The PPBC is a validated, global assessment tool using a 6-point Likert scale which requires patients to assess their bladder condition by selecting one of the following responses: 1=Does not cause me any problem at all; 2=Cause me some very minor problems; 3=Causes me some minor problems; 4=Causes me (some) moderate problems; 5=Causes me severe problems; 6=Causes me many severe problems
Improvement is defined by any reduction in PPBC score.
End of Treatment results include patients who had early discontinuation from the study.
Change is calculated as End of Treatment (EOT) - Baseline</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Population is full analysis set(FAS): all randomized patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Succinate</title>
            <description>5mg or 10mg tablet taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline in the Global Assessment Score of the Patient Perception of Bladder Condition (PPBC)</title>
          <description>The PPBC is a validated, global assessment tool using a 6-point Likert scale which requires patients to assess their bladder condition by selecting one of the following responses: 1=Does not cause me any problem at all; 2=Cause me some very minor problems; 3=Causes me some minor problems; 4=Causes me (some) moderate problems; 5=Causes me severe problems; 6=Causes me many severe problems
Improvement is defined by any reduction in PPBC score.
End of Treatment results include patients who had early discontinuation from the study.
Change is calculated as End of Treatment (EOT) - Baseline</description>
          <population>Population is full analysis set(FAS): all randomized patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improvement from Baseline to End of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Improvement from Baseline to End of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Treatment Benefit at the End of Treatment in the Global Assessment Score of the Benefit, Satisfaction, and Willingness (BSW) Questionnaire</title>
        <description>The BSW questionnaire is a validated instrument that can be used to assess patient satisfaction with antimuscarinic agents for OAB. It is designed to capture the patient's perception of the effect of treatment in terms of relative benefit, patient satisfaction, and patient intention or willingness to continue on therapy.</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>The number assessed included all participants who completed the BSW questionnaire at baseline visit (visit 2) and end of treatment (visit 5/early withdrawal).
A few patients who completed the BSW Questionnaire did not adequately complete the &quot; Benefits&quot; Section and therefore are considered 'N/A' for that Section.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Succinate</title>
            <description>5mg or 10mg tablet taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Treatment Benefit at the End of Treatment in the Global Assessment Score of the Benefit, Satisfaction, and Willingness (BSW) Questionnaire</title>
          <description>The BSW questionnaire is a validated instrument that can be used to assess patient satisfaction with antimuscarinic agents for OAB. It is designed to capture the patient's perception of the effect of treatment in terms of relative benefit, patient satisfaction, and patient intention or willingness to continue on therapy.</description>
          <population>The number assessed included all participants who completed the BSW questionnaire at baseline visit (visit 2) and end of treatment (visit 5/early withdrawal).
A few patients who completed the BSW Questionnaire did not adequately complete the &quot; Benefits&quot; Section and therefore are considered 'N/A' for that Section.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Benefit from Treatment - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Benefit from Treatment - Little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Benefit from Treatment - Much</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Benifit from Treatment - N/A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied with Treatment - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfied with Treatment - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                    <measurement group_id="O2" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Willingness to Continue - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Willingness to Continue - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Visit in the OAB-q HRQL Sub-domain Scores of Coping, Concern, Sleep and Social</title>
        <description>The OAB-q is used to assess how much a patient is bothered by OAB symptoms &amp; the impact on the patient's HRQL. It is comprised of 33 items, with raw scores for each sub-domain being converted to a scale of 0 to 100.
Higher score values are indicative of better HRQL, and a positive score in change from baseline indicates improvement.
Change is calculated End of Treatment (EOT) for each sub-domain – Baseline.</description>
        <time_frame>Baseline, Week 4, Week 8 and Week 12</time_frame>
        <population>Population is full analysis set(FAS): all randomized patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.
Number of participants analyzed per arm represents FAS. The numbers of participants for each visit/sub domain are noted in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Succinate</title>
            <description>5mg or 10mg tablet taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Each Visit in the OAB-q HRQL Sub-domain Scores of Coping, Concern, Sleep and Social</title>
          <description>The OAB-q is used to assess how much a patient is bothered by OAB symptoms &amp; the impact on the patient's HRQL. It is comprised of 33 items, with raw scores for each sub-domain being converted to a scale of 0 to 100.
Higher score values are indicative of better HRQL, and a positive score in change from baseline indicates improvement.
Change is calculated End of Treatment (EOT) for each sub-domain – Baseline.</description>
          <population>Population is full analysis set(FAS): all randomized patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.
Number of participants analyzed per arm represents FAS. The numbers of participants for each visit/sub domain are noted in the category titles.</population>
          <units>OAB-q HRQL Sub Domain Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Coping- Baseline (N= 374 ; 377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" spread="25.78"/>
                    <measurement group_id="O2" value="52.2" spread="26.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coping- Change at Week 4 (N=371; 370)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="21.55"/>
                    <measurement group_id="O2" value="22.2" spread="22.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coping- Change at Week 8 (N=342; 356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" spread="21.97"/>
                    <measurement group_id="O2" value="27.0" spread="24.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coping- Change at Week 12 (N=318; 339)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="22.56"/>
                    <measurement group_id="O2" value="28.8" spread="25.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concern- Baseline (N= 374 ; 377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" spread="25.49"/>
                    <measurement group_id="O2" value="51.9" spread="26.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concern- Change at Week 4 (N=371; 370)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="21.58"/>
                    <measurement group_id="O2" value="22.4" spread="23.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concern- Change at Week 8 (N=342; 356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" spread="22.87"/>
                    <measurement group_id="O2" value="28.4" spread="25.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concern- Change at Week 12 (N=318; 339)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="23.10"/>
                    <measurement group_id="O2" value="29.9" spread="26.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep- Baseline (N= 374 ; 377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3" spread="25.78"/>
                    <measurement group_id="O2" value="47.3" spread="27.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep- Change at Week 4 (N=371; 370)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="22.91"/>
                    <measurement group_id="O2" value="19.3" spread="23.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep- Change at Week 8 (N=342; 356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="24.46"/>
                    <measurement group_id="O2" value="26.2" spread="24.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep- Change at Week 12 (N=318; 339)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="24.65"/>
                    <measurement group_id="O2" value="27.5" spread="26.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social- Baseline (N= 374 ; 377)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" spread="23.13"/>
                    <measurement group_id="O2" value="78.7" spread="23.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social- Change at Week 4 (N=371; 370)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="16.51"/>
                    <measurement group_id="O2" value="10.3" spread="18.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social- Change at Week 8 (N=340; 356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="16.49"/>
                    <measurement group_id="O2" value="13.1" spread="19.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social- Change at Week 12 (N=318; 339)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="17.81"/>
                    <measurement group_id="O2" value="13.7" spread="21.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Work Productivity Assessment Index (WPAI)</title>
        <description>The WPAI is a tool used to evaluate the effect of solifenacin succinate on a patient's overall satisfaction &amp; quality of life, and included 6 questions regarding the effect that bladder condition had on ability to perform work-related functions &amp; carry out daily activities over the past 4 weeks. The scores were converted to percentages for reporting.
A negative score in Change from Baseline indicates improvement. End of Treatment results include patients who had early discontinuation from the study.
Change from baseline is based on the ANCOVA model after adjusting baseline value &amp; center.</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Population is full analysis set (FAS): all randomized patients who took at least 1 dose of double-blind study drug &amp; had an OAB-q assessment at both baseline &amp; at least 1 post-baseline visit.
The number of participants analyzed per arm represents FAS. The numbers of participants for each timepoint / parameter are noted in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Succinate</title>
            <description>5mg or 10mg tablet taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Work Productivity Assessment Index (WPAI)</title>
          <description>The WPAI is a tool used to evaluate the effect of solifenacin succinate on a patient's overall satisfaction &amp; quality of life, and included 6 questions regarding the effect that bladder condition had on ability to perform work-related functions &amp; carry out daily activities over the past 4 weeks. The scores were converted to percentages for reporting.
A negative score in Change from Baseline indicates improvement. End of Treatment results include patients who had early discontinuation from the study.
Change from baseline is based on the ANCOVA model after adjusting baseline value &amp; center.</description>
          <population>Population is full analysis set (FAS): all randomized patients who took at least 1 dose of double-blind study drug &amp; had an OAB-q assessment at both baseline &amp; at least 1 post-baseline visit.
The number of participants analyzed per arm represents FAS. The numbers of participants for each timepoint / parameter are noted in the category titles.</population>
          <units>Percentage of indicated parameter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% work time missed- Baseline (N=175;175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="8.60"/>
                    <measurement group_id="O2" value="1.1" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% work time missed- EOT (N=161;157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="5.85"/>
                    <measurement group_id="O2" value="0.5" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% work time missed- Change at EOT (N=145;142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="4.26"/>
                    <measurement group_id="O2" value="-0.5" spread="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% impairment while working- Baseline(N=203;194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="25.93"/>
                    <measurement group_id="O2" value="27.6" spread="25.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% impairment while working- EOT (N=193;197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="21.11"/>
                    <measurement group_id="O2" value="13.2" spread="18.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% impairment working-Change at EOT(N=172;175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="23.03"/>
                    <measurement group_id="O2" value="-14.6" spread="24.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% overall work impairment- Baseline (N=174;175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" spread="25.77"/>
                    <measurement group_id="O2" value="28.2" spread="25.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% overall work impairment- EOT (N=161;157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="21.81"/>
                    <measurement group_id="O2" value="14.1" spread="18.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%overall work impairment-Change at EOT(N=145;142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="22.59"/>
                    <measurement group_id="O2" value="-12.9" spread="23.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%activity impairment- Baseline (N=368;375)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" spread="28.36"/>
                    <measurement group_id="O2" value="37.3" spread="27.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% activity impairment- EOT (N=357;362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" spread="23.17"/>
                    <measurement group_id="O2" value="19.2" spread="22.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% activity impairment- Change at EOT(N=351;360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.7" spread="25.46"/>
                    <measurement group_id="O2" value="-18.1" spread="26.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Medical Care Use Index (MCUI) Medical Resource Utilization in the Past 3 Months</title>
        <description>MCUI is a Patient Reported Outcome instrument utilized to further evaluate the effect of solifenacin succinate on patient's overall satisfaction and quality of life.The tool included questions concerning the effect of the patients bladder condition on access to medical care.
A negative score in Change from Baseline indicates improvement.
End of Treatment results include patients who had early discontinuation from the study.
Change is calculated as End of Treatment (EOT) - Baseline</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Population is full analysis set(FAS):all randomized patients who took at least 1 dose of double-blind study medication &amp; had an assessment in OAB-q at both baseline &amp; at least 1 post-baseline visit. The number of participants analyzed per arm represents FAS. The numbers of participants for each timepoint/ parameter are noted in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Succinate</title>
            <description>5mg or 10mg tablet taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Medical Care Use Index (MCUI) Medical Resource Utilization in the Past 3 Months</title>
          <description>MCUI is a Patient Reported Outcome instrument utilized to further evaluate the effect of solifenacin succinate on patient's overall satisfaction and quality of life.The tool included questions concerning the effect of the patients bladder condition on access to medical care.
A negative score in Change from Baseline indicates improvement.
End of Treatment results include patients who had early discontinuation from the study.
Change is calculated as End of Treatment (EOT) - Baseline</description>
          <population>Population is full analysis set(FAS):all randomized patients who took at least 1 dose of double-blind study medication &amp; had an assessment in OAB-q at both baseline &amp; at least 1 post-baseline visit. The number of participants analyzed per arm represents FAS. The numbers of participants for each timepoint/ parameter are noted in the category titles.</population>
          <units>Number of categorical items</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>physician office visits- Baseline (N=371; 375)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.30"/>
                    <measurement group_id="O2" value="0.5" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>physician office visits- EOT (N=362; 366)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.62"/>
                    <measurement group_id="O2" value="0.2" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>physician office visits- Change at EOT(359; 365)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.29"/>
                    <measurement group_id="O2" value="-0.3" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>urinary tract infections-Baseline (N=371; 370)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.37"/>
                    <measurement group_id="O2" value="0.1" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>urinary tract infections- EOT (N=358; 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.28"/>
                    <measurement group_id="O2" value="0.1" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>urinary tract infections-Change at EOT (355; 356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.38"/>
                    <measurement group_id="O2" value="0.0" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>skin rashes- Baseline (N=367; 368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="10.52"/>
                    <measurement group_id="O2" value="0.3" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>skin rashes- EOT (N=354; 357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="7.70"/>
                    <measurement group_id="O2" value="0.2" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>skin rashes- Change at EOT (N=347; 351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="8.17"/>
                    <measurement group_id="O2" value="-0.1" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>falls- Baseline (N=365; 364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.86"/>
                    <measurement group_id="O2" value="0.2" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>falls- EOT (N=356; 358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.72"/>
                    <measurement group_id="O2" value="0.5" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>falls- Change at EOT (N=347; 349)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.69"/>
                    <measurement group_id="O2" value="0.2" spread="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pad/diapers used/ week- Baseline (N=371; 375)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="19.17"/>
                    <measurement group_id="O2" value="10.4" spread="20.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pad/diapers used/ week- EOT (N=360; 364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="24.07"/>
                    <measurement group_id="O2" value="8.3" spread="40.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pad/diapers used/ week- Change at EOT(N=357; 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="26.60"/>
                    <measurement group_id="O2" value="-2.1" spread="42.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the MCUI Behavior Therapy Stratified</title>
        <description>MCUI is a Patient Reported Outcome instrument utilized to further evaluate the effect of solifenacin succinate on patient's overall satisfaction and quality of life. The tool included questions concerning the effect of the patients bladder condition on access to medical care.
A negative score in Change from Baseline indicates improvement.
End of Treatment results include patients who had early discontinuation from the study.
Change is calculated as End of Treatment (EOT) - Baseline</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Population is full analysis set(FAS):all randomized patients who took at least 1 dose of double-blind study medication &amp; had an assessment in OAB-q at both baseline &amp; at least 1 post-baseline visit. The number of participants analyzed per arm represents FAS. The numbers of participants for each timepoint/ parameter are noted in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Succinate</title>
            <description>5mg or 10mg tablet taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the MCUI Behavior Therapy Stratified</title>
          <description>MCUI is a Patient Reported Outcome instrument utilized to further evaluate the effect of solifenacin succinate on patient's overall satisfaction and quality of life. The tool included questions concerning the effect of the patients bladder condition on access to medical care.
A negative score in Change from Baseline indicates improvement.
End of Treatment results include patients who had early discontinuation from the study.
Change is calculated as End of Treatment (EOT) - Baseline</description>
          <population>Population is full analysis set(FAS):all randomized patients who took at least 1 dose of double-blind study medication &amp; had an assessment in OAB-q at both baseline &amp; at least 1 post-baseline visit. The number of participants analyzed per arm represents FAS. The numbers of participants for each timepoint/ parameter are noted in the category titles.</population>
          <units>Number of Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>days with timed voiding- Baseline (N=364; 365)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="37.33"/>
                    <measurement group_id="O2" value="12.1" spread="29.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days with timed voiding- EOT (N=356; 360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="27.07"/>
                    <measurement group_id="O2" value="7.4" spread="23.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days with timed voiding-Change at EOT(N=347; 350)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="37.38"/>
                    <measurement group_id="O2" value="-5.3" spread="33.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days with fluid management-Baseline(N=368; 369)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="40.07"/>
                    <measurement group_id="O2" value="22.1" spread="38.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days with fluid management- EOT (N=355; 366)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="28.76"/>
                    <measurement group_id="O2" value="11.5" spread="25.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days with fluid management-Change at EOT(349; 360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="42.36"/>
                    <measurement group_id="O2" value="-11.0" spread="40.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days w/ pelvic floor exercises-Baseline(364; 366)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="22.17"/>
                    <measurement group_id="O2" value="9.2" spread="22.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days w/ pelvic floor exercises- EOT (N=352; 358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="56.94"/>
                    <measurement group_id="O2" value="5.5" spread="17.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days w/pelvic flr exercises-Change atEOT(344; 349)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="50.96"/>
                    <measurement group_id="O2" value="-3.2" spread="19.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days with biofeedback- Baseline (N=359; 360)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="5.32"/>
                    <measurement group_id="O2" value="0.1" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days with biofeedback- EOT (N=352; 358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.53"/>
                    <measurement group_id="O2" value="0.0" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days with biofeedback- Change at EOT (N=338; 343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="5.18"/>
                    <measurement group_id="O2" value="0.0" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days w/ electrical stimulation-Baseline (358; 362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.63"/>
                    <measurement group_id="O2" value="0.1" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days w/ electrical stimulation- EOT (N=352; 358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.43"/>
                    <measurement group_id="O2" value="0.1" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>days w/ elec stimulation-Change at EOT(N=337; 345)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.79"/>
                    <measurement group_id="O2" value="0.0" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in International Consultation on Incontinence Modular Questionnaire Male Sexual Matters Associated With Lower Urinary Tract Symptoms (ICIQ-MLUTSsex) Overall Symptom and Bother Scores.</title>
        <description>ICIQ-MLUTSsex is a patient reported outcome instrument to further evaluate the effect of solifenacin succinate on patients' overall satisfaction &amp; quality of life. The questionnaire contains 5 questions for detailed evaluation of sexual matters associated with lower urinary track symptoms &amp; impact on sexual quality of life, with a scale of 0 to 12.
Change from baseline with a negative score indicates improvement. End of Treatment results include patients who had early discontinuation. Change is calculated as End of Treatment(EOT)-Baseline.</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Population is full analysis set(FAS): all randomized male patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Succinate</title>
            <description>5mg or 10mg tablet taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in International Consultation on Incontinence Modular Questionnaire Male Sexual Matters Associated With Lower Urinary Tract Symptoms (ICIQ-MLUTSsex) Overall Symptom and Bother Scores.</title>
          <description>ICIQ-MLUTSsex is a patient reported outcome instrument to further evaluate the effect of solifenacin succinate on patients' overall satisfaction &amp; quality of life. The questionnaire contains 5 questions for detailed evaluation of sexual matters associated with lower urinary track symptoms &amp; impact on sexual quality of life, with a scale of 0 to 12.
Change from baseline with a negative score indicates improvement. End of Treatment results include patients who had early discontinuation. Change is calculated as End of Treatment(EOT)-Baseline.</description>
          <population>Population is full analysis set(FAS): all randomized male patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
          <units>ICIQ-MLUTSsex</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptom- Baseline (N=59; 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="2.81"/>
                    <measurement group_id="O2" value="3.5" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom- EOT (N=55; 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="2.71"/>
                    <measurement group_id="O2" value="3.7" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom- Change at EOT (N=54; 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.57"/>
                    <measurement group_id="O2" value="0.1" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bother- Baseline (N=59; 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="11.47"/>
                    <measurement group_id="O2" value="11.8" spread="11.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bother- EOT (N=51; 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="10.53"/>
                    <measurement group_id="O2" value="11.4" spread="11.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bother- Change at EOT (N=50; 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="8.24"/>
                    <measurement group_id="O2" value="-0.6" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in International Consultation on Incontinence Modular Questionnaire Female Sexual Matters Associated With Lower Urinary Tract Symptoms (ICIQ-FLUTSsex)Overall Symptom and Bother Scores.</title>
        <description>ICIQ-FLUTSsex is a patient reported outcome instrument to further evaluate the effect of solifenacin succinate on patients' overall satisfaction &amp; quality of life.The questionnaire contains 5 questions for detailed evaluation of sexual matters associated with lower urinary track symptoms &amp; impact on sexual quality of life, with a scale of 0 to 14.
Change from baseline with a negative score indicates improvement. End of Treatment results include patients who had early discontinuation. Change is calculated as End of Treatment(EOT)-Baseline.</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Population is full analysis set(FAS): all randomized female patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Succinate</title>
            <description>5mg or 10mg tablet taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in International Consultation on Incontinence Modular Questionnaire Female Sexual Matters Associated With Lower Urinary Tract Symptoms (ICIQ-FLUTSsex)Overall Symptom and Bother Scores.</title>
          <description>ICIQ-FLUTSsex is a patient reported outcome instrument to further evaluate the effect of solifenacin succinate on patients' overall satisfaction &amp; quality of life.The questionnaire contains 5 questions for detailed evaluation of sexual matters associated with lower urinary track symptoms &amp; impact on sexual quality of life, with a scale of 0 to 14.
Change from baseline with a negative score indicates improvement. End of Treatment results include patients who had early discontinuation. Change is calculated as End of Treatment(EOT)-Baseline.</description>
          <population>Population is full analysis set(FAS): all randomized female patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.
The number of participants analyzed per arm represents FAS. The numbers of participants for each visit are noted in the category titles.</population>
          <units>ICIQ-FLUTSsex</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptom- Baseline (N=302; 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="3.69"/>
                    <measurement group_id="O2" value="5.2" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom- EOT (N=297; 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="3.46"/>
                    <measurement group_id="O2" value="3.8" spread="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom- Change at EOT (N=288; 288)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="3.53"/>
                    <measurement group_id="O2" value="-1.3" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bother- Baseline (N=281; 282)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="10.77"/>
                    <measurement group_id="O2" value="10.0" spread="11.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bother- EOT (N=263; 262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="8.52"/>
                    <measurement group_id="O2" value="6.6" spread="9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bother- Change at EOT (N=245; 249)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="8.11"/>
                    <measurement group_id="O2" value="-3.6" spread="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Treatment Satisfaction Visual Analog Scale (TS-VAS)</title>
        <description>The TS-VAS is a instrument utilized to further evaluate the effect of solifenacin succinate on patients' overall satisfaction &amp; quality of life. Each patient completed a TS-VAS to rate satisfaction with treatment. They were to answer the following question: &quot;Are you satisfied with your treatment?&quot; by placing a mark on a line that ran from 0 (no, not at all) to 100 (yes, completely).
Change from baseline with a positive score indicates an improvement. The End of Treatment (EOT) results include patients who had early discontinuation from the study.
Change is calculated as EOT - Baseline</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Population is full analysis set(FAS): all randomized patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.
The number of participants analyzed per arm represents FAS. The numbers of participants for each row are noted in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Succinate</title>
            <description>5mg or 10mg tablet taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Treatment Satisfaction Visual Analog Scale (TS-VAS)</title>
          <description>The TS-VAS is a instrument utilized to further evaluate the effect of solifenacin succinate on patients' overall satisfaction &amp; quality of life. Each patient completed a TS-VAS to rate satisfaction with treatment. They were to answer the following question: &quot;Are you satisfied with your treatment?&quot; by placing a mark on a line that ran from 0 (no, not at all) to 100 (yes, completely).
Change from baseline with a positive score indicates an improvement. The End of Treatment (EOT) results include patients who had early discontinuation from the study.
Change is calculated as EOT - Baseline</description>
          <population>Population is full analysis set(FAS): all randomized patients who took at least 1 dose of double-blind study medication and had an assessment in OAB-q at both baseline and at least 1 post-baseline visit.
The number of participants analyzed per arm represents FAS. The numbers of participants for each row are noted in the category titles.</population>
          <units>TS-VAS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=363; 367)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" spread="35.29"/>
                    <measurement group_id="O2" value="29.0" spread="33.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment (N=363; 367)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" spread="38.10"/>
                    <measurement group_id="O2" value="67.4" spread="34.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at EOT (N=352; 357)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="47.28"/>
                    <measurement group_id="O2" value="38.2" spread="45.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical Analysis applies to 'Change at EOT'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-16.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-22.1</ci_lower_limit>
            <ci_upper_limit>-11.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Treatment in Mean Parameters Per 24 Hours Recorded in 3-day Diary</title>
        <description>The mean parameters recorded for previous 24 hours in the 3-day diary were: number of micturitions, number of incontinence episodes, number of urgency episodes, number of nocturia episodes and number of nocturnal voids.
Change from baseline with a lower score indicates an improvement.
End of Treatment (EOT) results include patients who had early discontinuation from the study; only patients who had the symptom at baseline and data at the EOT in the 3-day diary are included in the data table.
Change is calculated as EOT - Baseline</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>Population is full analysis set(FAS): all randomized patients who took at least 1 dose of double-blind study drug &amp; had an OAB-q assessment at both baseline &amp; at least 1 post-baseline visit.
The number of participants analyzed per arm represents FAS. The number of participants for each timepoint / parameter are noted in the category titles.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo tablet taken once daily</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Succinate</title>
            <description>5mg or 10mg tablet taken once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment in Mean Parameters Per 24 Hours Recorded in 3-day Diary</title>
          <description>The mean parameters recorded for previous 24 hours in the 3-day diary were: number of micturitions, number of incontinence episodes, number of urgency episodes, number of nocturia episodes and number of nocturnal voids.
Change from baseline with a lower score indicates an improvement.
End of Treatment (EOT) results include patients who had early discontinuation from the study; only patients who had the symptom at baseline and data at the EOT in the 3-day diary are included in the data table.
Change is calculated as EOT - Baseline</description>
          <population>Population is full analysis set(FAS): all randomized patients who took at least 1 dose of double-blind study drug &amp; had an OAB-q assessment at both baseline &amp; at least 1 post-baseline visit.
The number of participants analyzed per arm represents FAS. The number of participants for each timepoint / parameter are noted in the category titles.</population>
          <units>Number of Category Events / 24 Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Micturitions- Baseline (N=363;369)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.85" spread="4.039"/>
                    <measurement group_id="O2" value="11.73" spread="3.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Micturitions- End of Treatment (N=363;369)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.49" spread="3.645"/>
                    <measurement group_id="O2" value="9.50" spread="3.869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Micturitions- Change at EOT (N=363;369)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="3.203"/>
                    <measurement group_id="O2" value="-2.23" spread="3.482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incontinence Episodes- Baseline (N=267;268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="2.584"/>
                    <measurement group_id="O2" value="2.92" spread="2.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incontinence Episodes-End of Treatment (N=267;268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="2.338"/>
                    <measurement group_id="O2" value="1.07" spread="2.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incontinence Episodes-Change at EOT (N=267;268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="2.545"/>
                    <measurement group_id="O2" value="-1.85" spread="2.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urgency Episodes- Baseline (N=364;369)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.70" spread="3.895"/>
                    <measurement group_id="O2" value="5.72" spread="3.734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urgency Episodes- End of Treatment (N=364;369)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="3.795"/>
                    <measurement group_id="O2" value="2.66" spread="3.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urgency Episodes- Change at EOT (N=364;369)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.84" spread="3.891"/>
                    <measurement group_id="O2" value="-3.05" spread="3.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturia Episodes- Baseline (N=309;313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.968"/>
                    <measurement group_id="O2" value="1.74" spread="1.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturia Episodes- End of Treatment (N=309;313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="1.025"/>
                    <measurement group_id="O2" value="1.11" spread="1.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturia Episodes- Change at EOT (N=309;313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="1.015"/>
                    <measurement group_id="O2" value="-0.63" spread="1.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal Voids- Baseline (N=329;326)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="1.429"/>
                    <measurement group_id="O2" value="1.99" spread="1.520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal Voids- End of Treatment (N=329;326)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="1.299"/>
                    <measurement group_id="O2" value="1.29" spread="1.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal Voids- Change at EOT (N=329;326)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="1.542"/>
                    <measurement group_id="O2" value="-0.70" spread="1.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching placebo tablet taken once daily</description>
        </group>
        <group group_id="E2">
          <title>Solifenacin Succinate</title>
          <description>5mg or 10mg tablet taken once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (7.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Abdominal Strangulated Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Colitis Ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Migration of Implant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ammonia Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Intervertebral Discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ruptured Cerebral Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis Superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (7.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="386"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="382"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="386"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site’s manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Astellas Medical Monitor</name_or_title>
      <organization>Astellas Pharma Global Development</organization>
      <email>clinicaltrials@us.astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

